Cleveland Clinic Vasculitis Advances and Controversies 2025

Cleveland Clinic Vasculitis Advances and Controversies 2025

 Include: 22 videos + 18 pdfs, size: 10.2 GB

 Target Audience: rheumatologists, allergists/immunologists, dermatologists, internal medicine physicians

Information:

This comprehensive course dives into the complexities and innovations in the treatment and diagnosis of various forms of vasculitis. Participants will critically appraise emergent treatment options for small vessel vasculitis and large vessel vasculitis. In-depth evaluations will explore the central nervous system involvement in vasculitis and the current and future landscape of glucocorticoid use in vasculitis management.

The course will discuss advancements in imaging techniques for large vessel vasculitis and other diagnostic modalities. Participants will appraise the latest diagnostic approaches for giant cell arteritis (GCA), while evaluating the clinical evidence supporting the use of tocilizumab as a first-line therapy in GCA. Additionally, the role of plasma exchange in anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis will be thoroughly examined.

By the end of this course, participants will be equipped with the knowledge to effectively evaluate and implement cutting-edge treatments and diagnostic strategies in their practice.

Who Should Attend?

The Symposium is directed towards rheumatologists, allergists/immunologists, dermatologists, internal medicine physicians, nurse practitioners, nurses, and physician assistants interested in the treatment of vasculitis.

After completing this course, participants will be able to:

• Critically appraise emergent treatment options in small vessel vasculitis and large vessel vasculitis
• Evaluate CNS involvement in vasculitis
• Evaluate current and future landscape of glucocorticoid use in vasculitis management
• Discuss imaging advancement in large vessel vasculitis and other diagnostic modalities in vasculitis
• Appraise the diagnostic modalities in giant cell arteritis
• Evaluate the clinical evidence supporting the use of tocilizumab as a first-line therapy in GCA
• Appraise the role of plasma exchange in ANCA-associated vasculitis

 Topics:

• 1 Emergent treatment in small vessel vasculitis.pdf
  1 Emerging treatment in small vessel vasculitis.mp4
  2 Emergent treatment in large vessel vasculitis.mp4
  2 Emergent treatment in large vessel vasculitis.pdf
  3 EGPA – What can I offer to my patients.mp4
  3 EGPA – What can I offer to my patients.pdf
  4 Question & Answer.mp4
  5 Central Nervous System involvement in vasculitis.mp4
  5 Central Nervous System involvement in vasculitis.pdf
  6 Ask the Masters Challenging cases in vasculitis.mp4
  6 Ask the Masters Challenging cases in vasculitis.pdf
  7 Glucocorticoid use in small vessel vasculitis.mp4
  7 Glucocorticoid use in small vessel vasculitis.pdf
  8 Glucocorticoid use in large vessel vasculitis.mp4
  8 Glucocorticoid use in large vessel vasculitis.pdf
  9 Question & Answer.mp4
  10 Large vessel vasculitis imaging.mp4
  10 Large vessel vasculitis imaging.pdf
  11 Kidney pathology in small vessel vasculitis.mp4
  11 Kidney pathology in small vessel vasculitis.pdf
  12 Pathology in large vessel vasculitis.mp4
  12 Pathology in large vessel vasculitis.pdf
  13 Eye exam in giant cell arteritis.mp4
  13 Eye exam in giant cell arteritis.pdf
  14 Question & Answer.mp4
  15 Biopsy or imaging in the diagnosis of giant cell arteritis Tanaz Kermani, MD.mp4
  15 Biopsy or imaging in the diagnosis of giant cell arteritis Tanaz Kermani, MD.pdf
  16 Biopsy or imaging in the diagnosis of giant cell arteritis Kinanah Yaseen, MD.mp4
  16 Biopsy or imaging in the diagnosis of giant cell arteritis Kinanah Yaseen, MD.pdf
  17 Does plasma exchange have a role in ANCA associated vasculitis Ali Mehdi, MD.mp4
  17 Does plasma exchange have a role in ANCA associated vasculitis Ali Mehdi, MD.pdf
  18 Does plasma exchange have a role in ANCA associated vasculitis Alexandra Villa-Forte, MD.mp4
  18 Does plasma exchange have a role in ANCA associated vasculitis Alexandra Villa-Forte, MD.pdf
  19 Should Tocilizumab be used in every patient with giant cell arteritis Adam Brown, MD.mp4
  19 Should Tocilizumab be used in every patient with giant cell arteritis Adam Brown, MD.pdf
  20 Should Tocilizumab be used in every patient with giant cell arteritis Michael Putman, MD.mp4
  20 Should Tocilizumab be used in every patient with giant cell arteritis Michael Putman, MD.pdf
  21 Question & Answer.mp4
  Agenda.pdf
  May 8, 2025.mp4